Biomarkers of connective tissue disease-associated interstitial lung disease in bronchoalveolar lavage fluid: A label-free mass spectrometry-based relative quantification study

被引:6
|
作者
Ye, Jing [1 ]
Liu, Pengcheng [1 ]
Li, Renming [1 ]
Liu, Hui [1 ]
Pei, Wenjing [1 ]
Ma, Changxiu [1 ]
Shen, Bing [2 ]
Zhao, Dahai [1 ]
Chen, Xiaoyu [2 ]
机构
[1] Anhui Med Univ, Affiliated Hosp 2, Dept Pulm & Crit Care Med, Hefei, Peoples R China
[2] Anhui Med Univ, Sch Basic Med, 81 Meishan Rd, Hefei 230032, Anhui, Peoples R China
关键词
BALF; CTD-ILD; LC-MC; MS; pathogenesis; proteomics; JUNCTIONAL-ADHESION-MOLECULE; REVISED CRITERIA; O-GLYCOSYLATION; PROTEIN; CLASSIFICATION; POLYMYOSITIS; RECURRENCE; PNEUMONIA; MECHANISM;
D O I
10.1002/jcla.24367
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background The pathogenesis of connective tissue disease-associated interstitial lung disease (CTD-ILD) is unclear. This study aims to identify differentially expressed proteins (DEPs) in CTD-ILD to determine the potential role of these DEPs that may play in the pathogenesis of CTD-ILD and to offer potential therapeutic targets. Methods Bronchoalveolar lavage fluid (BALF) samples were collected from four patients with CTD-ILD and four patients without CTD-ILD. Label-free mass spectrometry-based relative quantification was used to identify the DEPs. Bioinformatics were used to determine the potential biological processes and signaling pathways associated with these DEPs. Results We found 65 upregulated DEPs including SFTPD, CADM1, ACSL4, TSTD1, CD163, LUM, SIGLEC1, CPB2, TGFBI and HGD, and 67 downregulated DEPs including SGSH, WIPF1, SIL1, RAB20, OAS3, GMPR2, PLBD1, DNAJC3, RNASET2 and OAS2. The results of GO functional annotation for the DEPs showed that the DEPS were mainly enriched in the binding, cellular anatomical entity, cellular processes, and biological regulation GO terms. The results of KEGG analyses showed that the pathways most annotated with the DEPs were complement and coagulation cascades, metabolic pathways, pathways in cancer, and PPAR signaling pathway. COG analyses further informed the functions associated with these DEPs, with most focused on signal transduction mechanisms; posttranslational modification, protein turnover, chaperones; intracellular trafficking, secretion, and vesicular transport; amino acid transport and metabolism; and lipid transport and metabolism. Conclusions DEPs identified between patients with vs. without CTD-ILD may play important roles in the development of CTD-ILD and are potential new biomarkers for early diagnosis of CTD-ILD.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] A Clue to Diagnosing Connective Tissue Disease-Associated Interstitial Lung Disease Response
    Fischer, Aryeh
    West, Sterling G.
    Swigris, Jeffrey J.
    Brown, Kevin K.
    du Bois, Roland M.
    CHEST, 2011, 139 (03) : 723 - 723
  • [42] Novel Therapeutic Approaches in Connective Tissue Disease-Associated Interstitial Lung Disease
    Mulcaire-Jones, Erica
    Pugashetti, Janelle Vu
    Oldham, Justin M.
    Khanna, Dinesh
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 45 (03) : 435 - 448
  • [43] New treatment paradigms for connective tissue disease-associated interstitial lung disease
    Kouranos, Vasileios
    Miranda, Gina
    Corte, Tamera J.
    Renzoni, Elisabetta A.
    CURRENT OPINION IN PULMONARY MEDICINE, 2018, 24 (05) : 453 - 460
  • [44] Successful Pregnancy Outcome with Connective Tissue Disease-Associated Interstitial Lung Disease
    Colbenson, G.
    Rose, C.
    Ernste, F.
    Ryu, J. H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [45] Rituximab Treatment For Chronic Connective Tissue Disease-Associated Interstitial Lung Disease
    Chartrand, S.
    Swigris, J. J.
    Peykova, L.
    Fischer, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [46] The role of biologics in treatment of connective tissue disease-associated interstitial lung disease
    Sharp, C.
    Dodds, N.
    Mayers, L.
    Millar, A. B.
    Gunawardena, H.
    Adamali, H.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2015, 108 (09) : 683 - 688
  • [47] Comment on: rituximab in autoimmune connective tissue disease-associated interstitial lung disease
    Uzunhan, Yurdagul
    Ferrah, Lila
    Brillet, Pierre-Yves
    Dhote, Robin
    Valeyre, Dominique
    Nunes, Hilario
    RHEUMATOLOGY, 2016, 55 (12) : 2279 - 2280
  • [48] Determining Respiratory Impairment in Connective Tissue Disease-Associated Interstitial Lung Disease
    Assayag, Deborah
    Ryerson, Christopher J.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2015, 41 (02) : 213 - +
  • [49] Connective tissue disease-associated interstitial lung disease: a series of 60 patients
    Chebbi, Donia
    Derbal, Samar
    Hentati, Olfa
    Cherif, Yousra
    Moussa, Ines
    Kammoun, Hela
    Ben Dahmen, Fatma
    Fekih, Leila
    Gharbi, Leila
    Abdallah, Meya
    Moussa, Ines
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [50] Autoantibodies Are Already Found in Connective Tissue Disease-Associated Interstitial Lung Disease
    Jearn, La-He
    Kim, Think-You
    CHEST, 2016, 150 (03) : 753 - 755